Angiodynamics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
AngioDynamics, Inc. announced its fiscal year 2026 results, highlighting a 9.5% increase in net sales driven by its Med Tech segment, while navigating a net loss and implementing strategic restructuring initiatives.
NASDAQ
AngioDynamics, a medical technology company, reported a significant reduction in net loss and an increase in gross margin for fiscal year 2025, driven by strong growth in its Med Tech segment and strategic divestitures, despite an overall revenue decline.
NASDAQ
10-K: AngioDynamics 2024 Annual Report: Strategic Shift to Outsourcing and Focus on High-Growth Med Tech
AngioDynamics' 2024 annual report highlights a strategic shift towards outsourcing manufacturing and focusing on high-growth Med Tech products, alongside significant financial impacts from divestitures and restructuring.